Tauriga Sciences Inc. Signs License Agreement With Targeted Medical Pharma Inc.
LOS ANGELES, July 16, 2014 (GLOBE NEWSWIRE) — Tauriga Sciences Inc. (OTCQB:TAUG) or (“Tauriga” or the “Company”), a diversified life sciences company, announced today it has signed a non-exclusive licensing agreement with Targeted Medical Pharma Inc. (OTCQB:TRGM) to reformulate and rebrand Targeted Medical’s medical food formulations into dietary supplements as part of Tauriga’s “Cannabis Complements” product line. Tauriga’s new Cannabis Complements product line will be formally launched later in the summer and consists of dietary supplements and other natural wellness products that do not contain cannabis oil and that will attempt to address cannabis-related effects, such as anxiety, memory and cognitive functions, and appetite control. The products to be offered under the “Cannabis Complements” line will contain “GRAS” ingredients, the U.S. Food and Drug Administration’s designation for ingredients that are “Generally Recognized as Safe”.
Lawrence A. May, M.D., Tauriga’s Chief Medical Officer and previously head of medical affairs at Herbalife, states, “I am enthusiastic about creating Tauriga’s Cannabis Complements product line to build our brand. We expect to first focus the products in the 23 medical marijuana states and then more broadly nationwide if the products are successful. Our formulations are based on established structure-function relationships, and these products will be consistent with the Company’s commitment to natural wellness.”
Tauriga Chairman and CEO Dr. Stella M. Sung adds, “Because the Cannabis Complements products do not contain cannabis, we believe they represent an opportunity to market across states and to generate immediate revenue upon launch. I believe there are synergistic benefits between our Cannabis Complements product line and the Honeywood/Doc Green’s product line we recently acquired through the Honeywood transaction.”
The initial products Tauriga plans to introduce under the Cannabis Complements line are Satietiva, an appetite suppressant, and Indicalm, an antiolytic supplement for anxiety. These products are not limited to cannabis-related effects but will be introduced to address the concerns of the demographic.
About Tauriga Sciences, Inc.:
Tauriga Sciences, Inc. (TAUG) is a diversified life sciences company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the synthetic biology space. The mission of the Company is to acquire and build a diversified portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. The Company’s business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. On July 13, 2014, Tauriga acquired a California based topical cannabis cream company.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG’s predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.